Lu Tian

Scientist II @ 858 Therapeutics

About

I work in preclinical drug discovery with a focus on oncology and immunology. My expertise is in 3D organoid culture derived from PDX and iPSC models, primary immune cells, and cell-based assays including viability, HTRF, and ELISA — applied to target validation and drug screening.I use these models to study mechanisms of action, resistance mechanisms, and signaling pathways. I enjoy troubleshooting complex experiments and I'm very hands-on in the lab.One thing I'm proud of is my ability to adapt quickly across different scientific areas — I've worked across oncology, stem cell biology, and immunology, and I find that breadth makes me a stronger, more creative scientist.Beyond the bench, I communicate my science clearly to different audiences — from cross-functional teams to senior leadership. I have presented my research at scientific conferences and to diverse audiences throughout my academic and industry career.I speak three languages fluently: Mandarin (native), French (native level), and English — an asset I've found valuable in collaborating across global teams and partnerships.

Country

United States

City

San Diego

Industry

Biotechnology

Skill

Cell differentiation, Gene editing, Small molecules, Drug screening, PDX, RNAscope, Tumorspheres, Intestinal organoids, Lung oraganoids, Cell therapy, iPSC, cell culture, flow cytometry, genetically modified mouse models, histology, Biologie moléculaire, Microscopie, Réaction en chaîne par polymérase, Biochimie, Biologie cellulaire

Experience

Scientist II

Osuna Therapeutics

2026-4 - Present · 6 mos

Сан-Диего, CA

Scientist II

858 Therapeutics

2023-3 - 2025-12 · 2 yrs 10 mos

Сан-Диего, CA

Small molecules, drug discovery, patient-derived xenograft (PDX) models, organoid cultures, drug screening, mechanisms of action

Scientist

Gracell Biotechnologies

2022-9 - 2023-2 · 6 mos

San Diego, Californie, États-Unis

Cell therapy, iPSC derived immune cells

Postdoctoral Fellow (lab relocation)

Icahn School of Medicine at Mount Sinai

2022-2 - 2022-8 · 7 mos

New York, New York, United States

Our laboratory relocated to Mount Sinai in January 2022. I continue to work on the following projects: • Establish lung organoid culture from human pluripotent stem cells to study lung development and model lung diseases : Use hPSC-derived lung organoids and human lung cells to study the subcellular localization of TMPRSS2 and its implication in SRAS-CoV-2 infection • Dissecting the molecular mechanisms to generate uniformized organoids

Postdoctoral Researcher

University of Southern California

2019-12 - 2022-1 · 2 yrs 2 mos

Los Angeles, California, United States

• Establish lung organoid culture from human pluripotent stem cells to study lung development and model lung diseases : Use hPSC-derived lung organoids and human lung cells to study the subcellular localization of TMPRSS2 and its implication in SRAS-CoV-2 infection • Dissecting the molecular mechanisms to generate uniformized organoids

Postdoctoral Fellow

UC Irvine

2018-7 - 2019-12 · 1 yr 6 mos

Irvine, California, United States

• Study the role of circadian disruption in the initiation and development of colorectal cancer - Use transgenic mouse model and intestinal organoid culture as tools to dissect the molecular and cellular mechanisms of circadian disruption in colon cancer

PhD student

CNRS UMR 8161-Institut de Biologie de Lille

2014-10 - 2018-3 · 3 yrs 6 mos

Région de Lille, France

- Used transgenic mouse model of mammary tumors (C3(1) Tag mice) and stem cell marker (s-SHIP-GFP mice) - Conducted cell and molecular biology tests and transcriptional profiling - Examined the role of synuclein gamma in resistance to radiation in breast cancer cells

Research Assistant

Université Pierre et Marie Curie

2013-9 - 2014-7 · 11 mos

Inserm U945

- Validate a cell-penetrating peptide (CPP) targeting a protein-protein interaction. - Evaluate the apoptotic effect of the CPP in cancer cell lines and human cancer cells